




LISTING OF CLAIMS

Claims 1-11 (CANCELED)

- 12- (currently amended) A composition comprising a combination of compound (A) of formula (I), ~~optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof, and clopidogrel or a pharmaceutically acceptable salt thereof :~~




optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof,
and clopidogrel or a pharmaceutically acceptable salt thereof.

- 13- (previously presented) The composition of Claim 12, wherein compound (A) has the (R) configuration.

- 14- (previously presented) The composition of Claim 12, wherein compound (A) is in the form of a sodium salt.

- 15- (previously presented) The composition of Claim 12, wherein clopidogrel is in the form of a hydrogen sulphate.

- 16- (currently amended) A pharmaceutical composition comprising as active ingredients a combination of compound (A) [,] of formula (I) :



optionally in the form of an optical isomer, or a pharmaceutically acceptable salt thereof, and clopidogrel or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable, inert excipients or carriers.

5 17- (currently amended) A pharmaceutical composition of Claim 16, wherein the compound (A) of formula (I) has the (R) configuration.

18- (previously presented) A pharmaceutical composition of Claim 16, wherein compound (A) is in the form of a sodium salt.

10 19- (previously presented) A pharmaceutical composition of Claim 16, wherein clopidogrel is in the form of a hydrogen sulphate.

20- (currently amended) A pharmaceutical composition of Claim 16, wherein the amounts of active ingredients are in the respective ranges of from 1 to 300 mg for the compound (A) of formula (I) and from 10 to 600 mg for clopidogrel.

15 21- (currently amended) A method for treating a cardiovascular illnesses illness involving activation of TP receptors, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

20 22- (currently amended) The method of Claim 21, wherein the cardiovascular illness is selected from acute coronary syndrome, stable or unstable angina, endothelial dysfunction, and vascular illnesses associated with atherosclerosis, hypertension, diabetes and heart failure.

23- (currently amended) A method for treating ~~or preventing~~ a disorder of the vascular, cardiovascular, or neurovascular system or a thrombo-embolic disorder, such method comprising administering to a living animal body, including a human, a therapeutically effective amount of a composition of Claim 12.

22 24 - (currently amended) The method of Claim 23, wherein the thrombo-embolic disorder ~~is associated with~~ results from atherosclerosis, auricular fibrillation and invasive surgical procedures in cardiology, neurology, vascular pathology and/or radiology.